Anthony Traboulsee

Professor
Website 
http://ms.vchri.ca
Degrees / Designations 

MD

Email Address 
t.traboulsee@ubc.ca
Phone 
604-822-0788
Fax 
604-297-9685
Mailing Address 
University of British Columbia Hospital 2211 Wesbrook Mall, room s-113 Vancouver, BC V6T 2B5 Canada
LinkedIn 
http://ca.linkedin.com/pub/tony-traboulsee/4/441/b15/

Biography

Academic Appointment 
Professor
Body Locations and Systems 
Multiple Sclerosis
Diagnosis and Therapy 
MRI Scans
Other Areas of Research 
NMO
Clinical Trial design

Anthony Traboulsee is a Professor and Research Chair of the MS Society of Canada at the University of British Columbia in Vancouver, Canada. He is Director of the MS/MRI Research Group, and Co-Director of the MS Clinical Trials Research Group at the University of British Columbia Hospital. His research focus is on the development of practice guidelines for routine use of MRI in the management of MS, establishing advanced MRI imaging outcomes in Multiple Sclerosis, and the treatment of Neuromyelitis Optica.

Current Projects 

NMO
MS
MRI
Clinical Trial Design

Clinical Trials 

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis (VISIONARY-MS)

Multiple Sclerosis

Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis

Multiple Sclerosis

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Multiple Sclerosis

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (AFFINITY)

Multiple Sclerosis

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (TOPAZ)

Multiple Sclerosis

Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD

Eye Disorders

Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients

Multiple Sclerosis

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (IGLOO)

Multiple Sclerosis, Neurologic Diseases

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Multiple Sclerosis

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis
News and Awards 
Mar 8, 2017Controversial “liberation therapy” fails to treat multiple sclerosis: UBC-Vancouver Coastal Health research
Jun 1, 2016UBC-Vancouver Coastal Health scientists find genetic cause of multiple sclerosis
Nov 21, 2015VCHRI centre recruits highest number of participants for international MS study
Feb 27, 2014New Centre for Brain Health to unite research and patient care
Nov 14, 2013Often ignored aspect of MRI proves highly useful for brain scans
Oct 17, 2013The ‘cents’ behind health research
Oct 8, 2013Study finds narrowing of veins is not unique to people with MS
Jun 25, 2013Prevalence and characteristics of aggressive MS identified
Publications